Table 3 Univariate progression-free survival analysis
From: A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
Intention-to-treat population (n = 40) | Intention-to-treat sub-population (n = 35) | |||||||
|---|---|---|---|---|---|---|---|---|
30 months-central PFS | P value | 30 months-CR PFS* | P value | 30 months-central PFS | P value | 30 months-CR PFS* | P value | |
Median age (years): | 0.11 | 0.057 | 0.15 | 0.051 | ||||
18–38 | 94% (83–100) | 77% (58–97) | 93% (79–100) | 80% (59–100) | ||||
>38 | 77% (56–97) | 46% (20–73) | 76% (55–97) | 45% (19–71) | ||||
Age (years): | <0.001 | 0.25 | <0.001 | 0.33 | ||||
18–50 | 93% (83–100) | 66% (48–83) | 92% (81–100) | 65% (46–84) | ||||
>50 | 57% (20–94) | 57% (20–94) | 57% (20–94) | 57% (20–94) | ||||
Sex (M/F): | 0.23 | 0.093 | 0.2 | 0.15 | ||||
Male | 77% (53–100) | 48% (21–75) | 73% (47–99) | 69% (47–91) | ||||
Female | 91% (78–100) | 72% (52–92) | 90% (76–100) | 50% (22–78) | ||||
Median time diagnosis to enrollment (range): | 0.85 | 0.93 | 0.62 | 0.95 | ||||
0–17 | 84% (67–100) | 62% (39–84) | 81% (61–100) | 61% (36–86) | ||||
>17 | 87% (71–100) | 64% (40–88) | 87% (70.100) | 63% (39–87) | ||||
Previous relapses: | 0.37 | 0.81 | 0.41 | 0.9 | ||||
No | 79% (58–100) | 65% (40–91) | 78% (56–100) | 62% (35–89) | ||||
Yes | 90% (77–100) | 61% (39–83) | 89% (74–100) | 62% (39–85) | ||||
Previous surgery: | 0.64 | 0.38 | 0.62 | 0.58 | ||||
No | 83% (65–100) | 73% (53–93) | 81% (61–100) | 70% (48–92) | ||||
Yes | 88% (75–100) | 52% (27–77) | 87% (70–100) | 55% (29–81) | ||||
Previous chemotherapy: | 0.37 | 0.6 | 0.37 | 0.44 | ||||
No | 83% (70–97) | 63% (45–81) | 81% (67–93) | 63% (44–82) | ||||
Yes | 100% (NA) | 60% (17–100) | 100% (NA) | 50% (1–99) | ||||
Location: | 0.15 | <0.001 | 0.16 | <0.001 | ||||
Head and neck & Proximal upper extremity | 71% (43–100) | 20% (0–51) | 71% (43–100) | 20% (0–51) | ||||
Other | 90% (77–100) | 81% (63–98) | 90% (77–100) | 80% (63–98) | ||||
ECOG baseline: | 0.32 | 0.18 | 0.22 | 0.43 | ||||
0 | 79% (59–100) | 80% (60–100) | 74% (49–99) | 75% (50–99) | ||||
1 | 90% (77–100) | 50% (27–73) | 89% (76–100) | 54% (30–77) | ||||
Local response: | 0.72 | 0.28 | 0.72 | 0.35 | ||||
PR | 90% (71–100) | 80% (55–100) | 89% (68–100) | 78% (51–100) | ||||
SD | 84% (69–99) | 56% (36–76) | 82% (66–98) | 56% (35–78 f) | ||||
Central response: | <0.001 | <0.001 | <0.001 | <0.001 | ||||
PR | 100% (NA) | 100% (NA) | 100% (NA) | 100% (NA) | ||||
SD | 84% (69–98) | 53% (33–73) | 83% (67–98) | 54% (33–75) | ||||
PD | 0% (NA) | 0% (NA) | 0% (NA) | 0% (NA) | ||||
Change in T2 enhance sequence (MRI)a: | 0.23 | 0.13 | 0.17 | 0.056 | ||||
0–7.5 | 94% (82–100) | 79% (57–100) | 94% (82–100) | 79% (57–100) | ||||
>7.5 | 77% (57–97) | 54% (30–78) | 73% (51–96) | 46% (20–71) | ||||
New score: | 0.63 | 0.42 | 0.53 | 0.25 | ||||
No change | 100% (NA) | 67% (13–100) | 100% (NA) | 67% (13–100) | ||||
0–4 | 90% (71–100) | 80% (55–100) | 90% (71–100) | 80% (55–100) | ||||
5–9 | 100% (NA) | 100% (NA) | 100% (NA) | 100% (NA) | ||||
>10 | 77% (57–97) | 54% (30–78) | 73% (51–96) | 46% (20–71) | ||||
Reduction in pain (BPI worst pain reduction) | 0.98 | 0.73 | 0.45 | 0.37 | ||||
At least −2 | 87% (65–100) | 56% (17–95) | 85% (72–99) | 50% (1–99) | ||||
<−2 | 85% (72–99) | 65% (47–83) | 75% (32–100) | 65% (47–83) | ||||
